Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Management Team
  • Product Portfolio
    • Respiratory
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
  • Corporate Presentation
Select Page
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS

by Fred Dumais | Apr 28, 2022 | News Release

MONTREAL, QUEBEC , April 28, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announces the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

by Fred Dumais | Apr 25, 2022 | News Release

MONTREAL, QUEBEC , April 25, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS

VALEO PHARMA ANNOUNCES LISTING OF CONVERTIBLE DEBENTURES ON TSX

by Fred Dumais | Apr 19, 2022 | News Release

MONTREAL, QUEBEC, April 19, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, is pleased to announce that the 12% Convertible Unsecured Subordinated Debentures (the “Debentures”)...
VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

VALEO PHARMA ANNOUNCES LISTING TO THE TORONTO STOCK EXCHANGE

by Fred Dumais | Mar 28, 2022 | News Release

The Company’s shares and warrants to start trading on March 29th, 2022 MONTREAL, QUEBEC , March 28, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has received final...
VALEO PHARMA REPORTS ITS FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS 

VALEO PHARMA REPORTS ITS FIRST QUARTER 2022 RESULTS AND HIGHLIGHTS 

by Fred Dumais | Mar 24, 2022 | News Release

Q1-22 revenues of $4.2 million, up 128% over Q1-21 Q1-22 gross margins of  $1.4 million, up 266% over Q1-21Public reimbursement secured in key provinces for  Enerzair, Atectura and Redesca$25.0 million convertible debenture financing completed MONTREAL,...
VALEO PHARMA SECURES ADDITIONAL PUBLIC REIMBURSEMENT FOR REDESCA™,  ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®

VALEO PHARMA SECURES ADDITIONAL PUBLIC REIMBURSEMENT FOR REDESCA™,  ENERZAIR® BREEZHALER® AND ATECTURA® BREEZHALER®

by Fred Dumais | Mar 22, 2022 | News Release

Canadian provincial public reimbursement now complete for Redesca with the addition of British Columbia Enerzair Breezhaler and Atectura Breezhaler reimbursement also secured for Saskatchewan and Prince Edward Island MONTREAL, QUEBEC , March 22, 2022 – Valeo Pharma...
« Older Entries

Recent News

  • VALEO PHARMA ANNONCE LES RÉSULTATS DE L’ASSEMBLÉE ANNUELLE DES ACTIONNAIRES, LES NOMINATIONS ET LES ATTRIBUTIONS D’OPTIONS ET D’UNITÉS D’ACTIONS RESTREINTES April 28, 2022
  • VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS, APPOINTMENTS AND OPTIONS AND RSU GRANTS April 28, 2022
  • VALEO PHARMA PRÉSENTERA À LA CONFÉRENCE POUR INVESTISSEURS SUR LA SANTÉ 2022 DE BLOOM BURTON & CO   April 25, 2022
  • VALEO PHARMA TO PRESENT AT THE 2022 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE   April 25, 2022

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
info@valeopharma.com
16667 Hymus Blvd.
Kirkland, QC H9H 4H9
  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

15 + 3 =